Aytu BioPharma delivered its Form 8-K financial results for the fiscal fourth quarter and full-year ended June 30, 2021 to the U.S. Securities and Exchange Commission last September 27. The company reported a $18.9 million net loss on $23.5 million in revenue. Product revenues climbed 58% from fiscal 2020, and the specialty pharmaceutical company’s net…
This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.
